Shares of Revolution Medicines, Inc. (RVMD) surged 7.48% in pre-market trading on Thursday, as multiple analysts raised their price targets for the biopharmaceutical company, signaling growing confidence in its growth prospects.

The wave of positive sentiment was led by JPMorgan analyst Brian Cheng, who not only raised the firm's price target on Revolution Medicines to $82 from $71 but also added the stock to the Analyst Focus List. Cheng maintained an Overweight rating on the shares. Similarly, Wedbush lifted its price target to $80 from $77, while keeping an Outperform rating on the stock.

Other notable upgrades included Leerink Partners raising its target price to $74 from $67, and LifeSci Capital's analyst Charles Zhu maintaining a Buy rating while boosting the price target to an impressive $104. According to FactSet, Revolution Medicines now has an average rating of Buy and a mean price target of $79.45. These upgrades reflect growing optimism about the company's pipeline and potential market opportunities, driving investor enthusiasm in the pre-market session.